CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 1,000 Shares

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Leonard E. Post sold 1,000 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $34.54, for a total transaction of $34,540.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

CG Oncology Trading Up 3.1 %

CG Oncology stock traded up $1.03 during mid-day trading on Friday, hitting $34.59. 661,823 shares of the company traded hands, compared to its average volume of 646,036. CG Oncology, Inc. has a one year low of $25.77 and a one year high of $50.23. The stock has a fifty day moving average price of $35.84 and a 200-day moving average price of $34.84.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.30 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. Analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a report on Friday. Roth Capital raised shares of CG Oncology to a "strong-buy" rating in a report on Tuesday, August 27th. UBS Group began coverage on CG Oncology in a report on Thursday, October 24th. They issued a "buy" rating and a $60.00 price target for the company. Bank of America reaffirmed a "buy" rating and issued a $65.00 price target on shares of CG Oncology in a report on Tuesday, October 8th. Finally, Roth Mkm initiated coverage on shares of CG Oncology in a research report on Tuesday, August 27th. They issued a "buy" rating and a $65.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, CG Oncology has a consensus rating of "Buy" and an average target price of $63.88.

Institutional Investors Weigh In On CG Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of CGON. Ally Bridge Group NY LLC lifted its position in CG Oncology by 50.5% in the third quarter. Ally Bridge Group NY LLC now owns 263,266 shares of the company's stock valued at $9,933,000 after purchasing an additional 88,390 shares during the last quarter. Deerfield Management Company L.P. Series C raised its holdings in CG Oncology by 811.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 433,540 shares of the company's stock valued at $13,687,000 after buying an additional 386,000 shares during the last quarter. Ensign Peak Advisors Inc bought a new stake in CG Oncology during the 2nd quarter valued at $1,912,000. SG Americas Securities LLC bought a new stake in CG Oncology during the 3rd quarter valued at $664,000. Finally, Bank of New York Mellon Corp raised its holdings in CG Oncology by 38.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 89,344 shares of the company's stock valued at $2,821,000 after buying an additional 24,801 shares during the last quarter. Institutional investors own 26.56% of the company's stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.